Gapping down
In reaction to disappointing earnings/guidance:
- DXTR -23.4%, KONA -20.9%, RELY -17.6%, BIOC -16.1%, SSKN -14.9%, RHE -12.5%, LPTH -11.8%, CLRB -11.6%, PBYI -11.2%, WAC -10.8%, TTD -10.2%, ESL -9.4%, RDFN -8.6%, QTM -8.2%, TPC -7.3%, AIRG -6.1%, CLIR -5.7%, AVGR -4.8%, XIN -3.6%, FH -3.3%, XON -3%, XELA -3%, ACRX -2.6%, BPTH -2.1%, ESNC -2%, CRMD -1.9%, JWN -1.6%, ONVO -1.3%, FSIC -1.3%, KDMN -1.1%, IPWR -1%, EFX -1%
Other news:
- NVCN -14.4% (prices offering of 6,609,588 Series A units of Neovasc and 19,066,780 Series B units of the Co, at a price of $1.46 per Unit)
- INFI -13.6% (reports clinical and translational data for IPI-549; well tolerated and demonstrated clinical activity)
- ATTO -7% (prices secondary offering by selling shareholder of 12,295,082 ordinary shares at $9.00 per share)
- HRTX -3.7% (announces FDA approval of CINVANTI injectable emulsion, for intravenous infusion)
- ARLZ -1% (files for $100 mln mixed securities shelf offering)
Analyst comments:
- MRO -0.5% (downgraded to Neutral from Buy at Citigroup)
